- Home
- KPTI vs CVRX Comparison
KPTI vs CVRX Comparison
Compare KPTI & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | CVRX |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.8M | 160.8M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KPTI | CVRX |
|---|---|---|
| Price | $9.02 | $5.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $16.00 | $10.50 |
| AVG Volume (30 Days) | ★ 434.6K | 353.4K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | $22.36 | $17.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.57 | ★ 10.45 |
| 52 Week Low | $3.65 | $4.37 |
| 52 Week High | $10.99 | $11.30 |
Technical Indicators
Market Signals| Indicator | KPTI | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 34.85 |
| Support Level | $5.43 | $5.06 |
| Resistance Level | $9.32 | $8.10 |
| Average True Range (ATR) | 0.81 | 0.55 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 66.13 | 26.46 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.